Immunology Today—March 11, 2026

LucidQuest

42 minutes ago

This week’s Immunology update highlights regulatory progress, positive late-stage clinical data, major licensing deals, and continued pipeline investment across autoimmune and inflammatory diseases.

In Today’s Newsletter

Dive deeper

🧬 Roche Gazyva/Gazyvaro posts Phase 3 SLE win [1] [06 Mar 2026]

https://www.roche.com/media/releases/med-cor-2026-03-06
Context: The trial enrolled adults with systemic lupus erythematosus, n=151 on Gazyva/Gazyvaro and n=152 on placebo; Roche also reported benefit across key secondary endpoints, including BICLA, steroid reduction, SRI-6, flare timing, remission, and LLDAS.
Key point: Gazyva/Gazyvaro (Roche; obinutuzumab, anti-CD20) improved SRI-4 response at Week 52 versus placebo plus standard therapy in Phase 3 ALLEGORY, 76.7% versus 53.5% (p<0.001).
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Pfizer advances tilrekimig after positive atopic dermatitis Phase 2 [2] [09 Mar 2026]

https://www.pfizer.com/news/press-release/press-release-detail/pfizers-phase-2-study-trispecific-antibody-positive
Context: Pfizer described the ongoing study as randomized, double-blind, and placebo-controlled; Stage 2 monthly dosing showed placebo-adjusted EASI-75 rates of 38.7%, 51.9%, and 49.4%, and the company said safety was favorable with no dose-dependent signal.
Key point: Tilrekimig (Pfizer; PF-07275315, trispecific antibody) met the primary endpoint in moderate to severe atopic dermatitis, with statistically significant EASI-75 improvement at Week 16 across all tested doses versus placebo.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 GSK out-licenses linerixibat to Alfasigma [3] [09 Mar 2026]

https://www.gsk.com/en-gb/media/press-releases/gsk-and-alfasigma-announce-agreement/
Context: Marketing applications are under review in the US, EU, UK, China, and Canada, based on positive Phase 3 GLISTEN data; GSK will receive $300 million upfront plus regulatory and sales-based milestones and royalties.
Key point: Alfasigma will acquire worldwide exclusive rights to develop, manufacture, and commercialise linerixibat (investigational IBAT inhibitor) from GSK for cholestatic pruritus in primary biliary cholangitis.
Implication: Signals pipeline investment and modality expansion.

💰 Teva secures Blackstone funding for duvakitug Phase 3 [4] [US • 03 Mar 2026]

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Blackstone-Life-Sciences-Announce-400-Million-Strategic-Growth-Capital-Agreement-to-Advance-duvakitug/default.aspx
Context: Duvakitug is in Phase 3 studies for ulcerative colitis and Crohn’s disease; Teva said the asset is co-developed with Sanofi under a separate agreement and that Blackstone is eligible for milestones and royalties.
Key point: Blackstone Life Sciences will provide $400 million over four years to support development of duvakitug (Teva; TL1A monoclonal antibody).
Implication: Signals pipeline investment and modality expansion.

✅ Bristol Myers Squibb wins US approval for Sotyktu in PsA [5] [US • 06 Mar 2026]

https://news.bms.com/news/corporate-financial/2026/U-S–FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/default.aspx
Context: Approval was based on Phase 3 POETYK PsA-1 and PsA-2, where ACR20 at Week 16 was 54% versus 34% and 54% versus 39%, respectively; the company also reported MDA improvement and a safety profile generally consistent with plaque psoriasis.
Key point: The US FDA approved Sotyktu (Bristol Myers Squibb; deucravacitinib, TYK2 inhibitor) for adults with active psoriatic arthritis.
Implication: Introduces competition that may affect pricing and formulary access.

🏃 Johnson & Johnson wins Fast Track for nipocalimab in SLE [6] [US • 03 Mar 2026]

https://www.jnj.com/media-center/press-releases/johnson-johnson-therapy-nipocalimab-granted-u-s-fda-fast-track-designation-in-systemic-lupus-erythematosus-sle
Context: Johnson & Johnson said the designation was supported by positive Phase 2b JASMINE results, including reduced disease activity and steroid-sparing potential, and that Phase 3 GARDENIA is actively enrolling adults with active SLE.
Key point: Nipocalimab (Johnson & Johnson; FcRn blocker) received US FDA Fast Track designation in systemic lupus erythematosus.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 Galderma raises Nemluvio peak sales view after launch momentum [7] [05 Mar 2026]

https://www.fiercepharma.com/pharma/galderma-doubles-nemluvio-peak-sales-projection-4b-after-strong-atopic-dermatitis-launch
Context: Fierce Pharma reported 2025 Nemluvio sales of $452 million, with adoption in atopic dermatitis and prurigo nodularis, and noted Galderma’s comments on strong launch trajectory, physician experience, and growing access.
Key point: Galderma raised projected peak annual sales for Nemluvio (nemolizumab; IL-31 receptor inhibitor) to above $4 billion, from above $2 billion previously.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🛑 Kyowa Kirin halts late-stage rocatinlimab program [8] [03 Mar 2026]

https://www.dermatologytimes.com/view/kyowa-kirin-ends-late-stage-ox40-development
Context: Dermatology Times reported new malignancy concerns, including confirmed and suspected Kaposi sarcoma cases; the article also noted prior Phase 3 efficacy in atopic dermatitis and expected regulatory filing plans before the halt.
Key point: Kyowa Kirin discontinued rocatinlimab development across atopic dermatitis, prurigo nodularis, and asthma after a program-wide safety review with Amgen.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 AI tumor-shape metrics show prognostic signal in melanoma [9] [09 Mar 2026]

https://www.dermatologytimes.com/view/ai-derived-tumor-shape-metrics-show-prognostic-potential-in-melanoma
Context: Dermatology Times described a 745-case, five-cohort analysis in the UK, Australia, and the Czech Republic; minor axis length strongly correlated with Breslow thickness, and adding Nodularity Index modestly improved 5-year melanoma-specific survival prediction.
Key point: An AI-based pathology study identified tumor morphometrics, including a Nodularity Index, with prognostic associations in melanoma.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Systemic lupus erythematosus had two notable updates this week, Roche’s Phase 3 obinutuzumab data [1] and Johnson & Johnson’s Fast Track progress with nipocalimab [6].
Atopic dermatitis remains highly active, with Pfizer moving tilrekimig toward Phase 3 [2], Galderma upgrading Nemluvio commercial expectations [7], and Kyowa Kirin stopping rocatinlimab despite late-stage efficacy signals [8].
Deal activity stayed strong in specialty and rare disease, with Alfasigma taking global rights to linerixibat from GSK [3] and Blackstone funding Teva’s duvakitug program [4].
Bristol Myers Squibb’s Sotyktu approval adds a new oral option in psoriatic arthritis and expands TYK2’s role beyond psoriasis [5].
AI-enabled pathology continues to move toward clinically useful melanoma risk stratification, though the latest results remain observational and retrospective [9].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Immunology archive on our research hub page.

FAQ

What did Roche’s ALLEGORY trial show for Gazyva/Gazyvaro in SLE?

Roche said Gazyva/Gazyvaro (obinutuzumab) improved SRI-4 response at Week 52 versus placebo plus standard therapy in Phase 3 ALLEGORY, and also met key secondary endpoints including BICLA and steroid reduction [1].

Is Pfizer’s tilrekimig moving into Phase 3 for atopic dermatitis?

Yes. Pfizer said positive Phase 2 topline data support Phase 3 development, and a pivotal atopic dermatitis study is on track to start in 2026 [2].

What is the status of linerixibat after the GSK–Alfasigma deal?

Linerixibat is still investigational. GSK said marketing applications are under review in the US, EU, UK, China, and Canada, and Alfasigma is taking worldwide rights under the new agreement [3].

What does the Sotyktu approval cover in psoriatic arthritis?

The US FDA approved Sotyktu for adults with active psoriatic arthritis. Bristol Myers Squibb said the decision was based on POETYK PsA-1 and PsA-2, which met the ACR20 primary endpoint at Week 16 [5].

Why was rocatinlimab discontinued despite positive late-stage data?

Kyowa Kirin said the program was stopped after safety review identified malignancy concerns, including confirmed and suspected Kaposi sarcoma cases. The article notes causality was not established, but the benefit-risk profile changed [8].

What is the Nodularity Index in melanoma, and why does it matter?

The study summarized by Dermatology Times defined Nodularity Index as tumor depth relative to width. Higher values were linked with poorer outcomes and added modest prognostic value beyond digital Breslow thickness and AJCC staging [9].

Entities / Keywords

Gazyva/Gazyvaro (obinutuzumab, anti-CD20, Roche)
Systemic lupus erythematosus (SLE, lupus)
ALLEGORY (Phase 3 SLE trial)
Tilrekimig (PF-07275315, trispecific antibody, Pfizer)
Atopic dermatitis (AD, eczema)
Linerixibat (IBAT inhibitor, primary biliary cholangitis pruritus)
Primary biliary cholangitis (PBC, cholestatic pruritus)
Duvakitug (TL1A monoclonal antibody, Teva, Sanofi)
Ulcerative colitis (UC)
Crohn’s disease (CD)
Sotyktu (deucravacitinib, TYK2 inhibitor, Bristol Myers Squibb)
Psoriatic arthritis (PsA)
Nipocalimab (FcRn blocker, Johnson & Johnson)
Nemluvio (nemolizumab, IL-31 receptor inhibitor, Galderma)
Prurigo nodularis (PN)
Rocatinlimab (anti-OX40 monoclonal antibody, Kyowa Kirin, Amgen)
OX40 pathway (OX40 modulation, T-cell costimulation)
Melanoma AI pathology (digital Breslow thickness, Nodularity Index)